Search results
Results from the WOW.Com Content Network
Romosozumab, sold under the brand name Evenity (/ ɪ ˈ v ɛ n ɪ t i / ih-VENN-ih-tee or with the pin-pen merger, / ɪ ˈ v ɪ n ɪ t i / ih-VINN-ih-tee), is a medication used to treat osteoporosis. [ 7 ] [ 8 ] It has been found to decrease the risk of fractures of the spine .
2017: The FDA approved Parsabiv in February [73] and Mvasi (bevacizumab-awwb) in September. [74] 2018:Amgen began constructing a next-generation biomanufacturing plant at its West Greenwich, Rhode Island, campus in July. [75] 2019: In January, Evenity (romosozumab) received approval in Japan, [76] [77] followed by FDA approval in April. [78]
Amgen (AMGN) gets approval in the United States for osteoporosis drug, Evenity. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ...
The EC grants marketing authorization to Amgen (AMGN) and partner UCB's Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
The CHMP provides an unfavorable feedback to Amgen's (AMGN) marketing application for Evenity to treat severe osteoporosis in postmenopausal women with risk of fracture.
Use in pregnancy is known to harm the baby. [3] Bendamustine is in the alkylating agents family of medication. [3] It works by interfering with the function of DNA and RNA. [3] Bendamustine was approved for medical use in the United States in 2008. [3] It is on the World Health Organization's List of Essential Medicines.
For premium support please call: 800-290-4726 more ways to reach us
Idecabtagene vicleucel was approved for medical use in the United States in March 2021. [4] [7] It is the first cell-based gene therapy approved by the US Food and Drug Administration (FDA) for the treatment of multiple myeloma. [4] [7] It was approved for medical use in the European Union in August 2021. [5] [9]